KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accounts Payables (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Accounts Payables for 8 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 171.13% to $18.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2025, up 171.13% year-over-year, with the annual reading at $18.7 million for FY2025, 171.13% up from the prior year.
  • Accounts Payables hit $18.7 million in Q4 2025 for Castle Biosciences, up from $12.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $18.7 million in Q4 2025 to a low of $1.4 million in Q2 2021.
  • Historically, Accounts Payables has averaged $7.3 million across 5 years, with a median of $6.9 million in 2023.
  • Biggest five-year swings in Accounts Payables: crashed 45.17% in 2021 and later soared 200.57% in 2023.
  • Year by year, Accounts Payables stood at $2.5 million in 2021, then skyrocketed by 85.82% to $4.7 million in 2022, then surged by 117.04% to $10.3 million in 2023, then plummeted by 32.79% to $6.9 million in 2024, then soared by 171.13% to $18.7 million in 2025.
  • Business Quant data shows Accounts Payables for CSTL at $18.7 million in Q4 2025, $12.2 million in Q3 2025, and $13.2 million in Q2 2025.